Effect of dialyzer reuse on complement activation and neutropenia in hemodialysis. 1984

D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt

A prospective study of 10 patients undergoing hemodialysis showed that less neutropenia and complement activation occurred with dialyzer reuse. Neutrophil counts fell 95% +/- 5% (SEM) with first use and 66% +/- 8% and 48% +/- 10% with second and third uses, respectively (p less than 0.05). The production of complement component C5a-desarg, as measured by the bioassay granulocyte aggregation, was decreased by 96% +/- 1% and 93% +/- 2% with second and third uses, respectively (p less than 0.05). We investigated the role of the dialyzer disinfectant formaldehyde in decreased neutropenia. In vitro, formaldehyde inhibited granulocyte aggregation and chemotaxis and the dialyzer membrane's ability to generate granulocyte aggregating activity; however, this occurred only at concentrations higher than those likely to obtain in patients. The ability of dialysis membranes to generate granulocyte aggregating activity in plasma was decreased 55% +/- 5% by their prior sequential preincubation in plasma and then formalin (p less than 0.05) and extensive rinsing, which is similar to the circumstances obtaining with dialyzer reuse. Preincubation of membranes in plasma or formalin alone resulted in no change in the membrane's ability to generate granulocyte aggregating activity. We conclude that the exposure of membranes to both plasma and formalin during dialysis and storage is responsible for the decreased C5a-desarg production with reuse, probably because plasma proteins are fixed to the membrane in such a way that interrupts free interaction between the membrane and plasma complement components.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D015937 Complement C5a, des-Arginine A derivative of complement C5a, generated when the carboxy-terminal ARGININE is removed by CARBOXYPEPTIDASE B present in normal human serum. C5a des-Arg shows complete loss of spasmogenic activity though it retains some chemotactic ability (CHEMOATTRACTANTS). C5 a, des-Arg,C5 a, des-Arginine,C5a des-Arg,C5a des-Arginine,C5a, des-Arg,C5a, des-Arginine,Complement 5a, de-Arginine,Complement 5a, des-Arginine,C5 a, des Arg,C5 a, des Arginine,C5a des Arginine,C5a, des Arg,C5a, des Arginine,C5a, des-Arginine Complement,Complement 5a, de Arginine,Complement 5a, des Arginine,Complement C5a, des Arginine,de-Arginine Complement 5a,des-Arg C5 a,des-Arg C5a,des-Arg, C5a,des-Arginine C5 a,des-Arginine C5a,des-Arginine Complement 5a,des-Arginine Complement C5a,des-Arginine, C5a

Related Publications

D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 1984, Uremia investigation,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 1980, Proceedings of the Clinical Dialysis and Transplant Forum,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
August 1996, JAMA,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 1980, Transactions - American Society for Artificial Internal Organs,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 1987, American journal of nephrology,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
April 1990, Artificial organs,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 2022, Indian journal of nephrology,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 2019, Blood purification,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 1992, American journal of nephrology,
D F Stroncek, and P Keshaviah, and P R Craddock, and D E Hammerschmidt
January 1982, Nephron,
Copied contents to your clipboard!